Indoco Remedies Limited (INDOCO) fundamentals
Indoco Remedies Limited is a listed company in Pharmaceuticals & Biotechnology, part of the Healthcare sector, listed on the NSE as INDOCO (ISIN INE873D01024). This page carries its reported financials, balance sheet, cash flow, shareholding pattern and valuation ratios.
What Indoco Remedies Limited does
Indoco Remedies Limited is an India-based fully integrated, research-oriented pharmaceutical company. The Company is engaged in the manufacturing and marketing of formulations (finished dosage forms) and active pharmaceutical ingredients (APIs). The Company caters to both Domestic and International markets. Its products include SENSODENT-K, HOMIDE, DEXOREN-S, LORCHEK-MR, SENSOFORM, KIDODENT, NINAF, KARVOL PLUS, CYCLOPAM, LIGNOX+ADRENLINE, NOXA, CITAL-UTI, RENOLEN, REXIDIN-M, CITAL, SENSODENT-KF, CARMICIDE, TOBAREN-DM, FEBREX PLUS, SCABEX, CLOBEN-G, MOFLOREN-BF, OTOREX, ZINCOREN, SENOLIN, LIGNOX, HEMSYL, FEDRIS, REXIDIN, VEPAN, OXIPOD, TURBOCORT, MACUCHEK, and DENTOGEL. The Company has around 11 manufacturing facilities, seven for finished dosage forms (FDFs) and four for active pharmaceutical ingredients (APIs), supported by a research and development center and a clinical research organization facility.
Valuation and market data
| Last close | ₹263.02 |
|---|---|
| Market capitalisation | ₹2,426 crore |
| Enterprise value | ₹3,008 crore |
| P/E (TTM) | 0.00 |
| Price to book | 2.60 |
| Price to sales (TTM) | 0.75 |
| Book value per share | ₹101.07 |
| Dividend yield | 0.00% |
| Sector | Healthcare |
| Industry | Pharmaceuticals & Biotechnology |
| Listed since | Fri Jan 14 |
Annual results
| Period | Revenue | Profit before tax | Net profit | EPS |
|---|---|---|---|---|
| Mar 2026 | ₹1,716 crore | ₹-11 crore | ₹-6 crore | -0.61 |
| Mar 2025 | ₹1,537 crore | ₹-7 crore | ₹-9 crore | -0.95 |
| Mar 2024 | ₹1,799 crore | ₹153 crore | ₹117 crore | 12.66 |
| Mar 2023 | ₹1,669 crore | ₹192 crore | ₹141 crore | 15.34 |
| Mar 2022 | ₹1,542 crore | ₹236 crore | ₹155 crore | 16.77 |
Figures are as reported (standalone), in ₹ crore.
Shareholding pattern
As of Jun 2026:
| Promoters | 58.9% |
|---|---|
| Foreign institutions (FII) | 1.3% |
| Mutual funds | 17.2% |
| Other domestic institutions | 0.5% |
| Retail and others | 22.2% |
More on BreakPoint
FundaX company research covers every listed company with reported financials. BreakPoint Pro adds the BreakPoint iQ score, the screener and the multibagger board.
Data is sourced from exchange filings and vendor feeds and is for research, not investment advice. Figures can be restated by the company after publication.